Financials Healios K.K.

Equities

4593

JP3835100003

Biotechnology & Medical Research

Delayed Japan Exchange 10:26:55 2024-07-15 pm EDT 5-day change 1st Jan Change
183 JPY 0.00% Intraday chart for Healios K.K. +7.02% +10.91%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 101,628 70,754 16,537 12,300 16,494 - -
Enterprise Value (EV) 1 101,628 67,584 16,436 9,986 16,494 16,494 16,494
P/E ratio -18.3 x -13.7 x -2.96 x -2.93 x -4.59 x -5.5 x -5.41 x
Yield - - - - - - -
Capitalization / Revenue 3,764 x 1,726 x 184 x 102 x 55 x 11.8 x 7.16 x
EV / Revenue 3,764 x 1,726 x 184 x 102 x 55 x 11.8 x 7.16 x
EV / EBITDA - - -3.45 x -3.43 x -22.9 x -22.9 x -
EV / FCF -23.6 x - - -4.32 x -2.82 x -10.8 x -6.01 x
FCF Yield -4.24% - - -23.2% -35.5% -9.26% -16.6%
Price to Book 13 x 8.19 x 3.87 x 3.19 x 4.84 x 39.8 x -9.84 x
Nbr of stocks (in thousands) 51,666 55,148 61,704 74,543 90,130 - -
Reference price 2 1,967 1,283 268.0 165.0 183.0 183.0 183.0
Announcement Date 2/12/21 2/14/22 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 27 41 90 121 300 1,392 2,304
EBITDA 1 - - -4,793 -3,589 -719 -719 -
EBIT 1 -4,183 -5,384 -5,179 -3,379 -2,889 -2,633 -2,580
Operating Margin -15,492.59% -13,131.71% -5,754.44% -2,792.56% -963% -189.08% -111.95%
Earnings before Tax (EBT) 1 -5,378 -4,462 -5,330 -3,626 -3,289 -2,756 -3,097
Net income 1 -5,512 -4,910 -5,169 -3,823 -3,289 -2,761 -2,708
Net margin -20,414.81% -11,975.61% -5,743.33% -3,159.5% -1,096.33% -198.28% -117.51%
EPS 2 -107.2 -93.36 -90.67 -56.22 -39.90 -33.29 -33.80
Free Cash Flow 1 -4,307 - - -2,850 -5,853 -1,528 -2,745
FCF margin -15,951.85% - - -2,355.37% -1,951% -109.73% -119.11%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 2/12/21 2/14/22 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1
Net sales 1 14 20 11 11 22 8 60 7 101 108 6 - 10
EBITDA - - - - - - - - - - - - -
EBIT 1 -1,849 -2,443 -1,429 -1,635 -3,064 -1,041 -1,074 -888 -667 -1,555 -743 -1,081 -1,049
Operating Margin -13,207.14% -12,215% -12,990.91% -14,863.64% -13,927.27% -13,012.5% -1,790% -12,685.71% -660.4% -1,439.81% -12,383.33% - -10,490%
Earnings before Tax (EBT) 1 -2,624 -1,807 -1,415 - -3,213 -1,056 - -735 - -1,321 -709 - -2,511
Net income 1 -2,608 -1,892 -1,460 - -3,260 -696 - -732 - -1,392 -700 - -2,424
Net margin -18,628.57% -9,460% -13,272.73% - -14,818.18% -8,700% - -10,457.14% - -1,288.89% -11,666.67% - -24,240%
EPS 2 -50.82 -36.60 -26.48 -32.63 -59.11 -12.02 -19.54 -11.51 -10.37 -21.88 -9.910 -24.43 -29.05
Dividend per Share - - - - - - - - - - - - -
Announcement Date 8/6/20 8/10/21 5/10/22 8/9/22 8/9/22 11/14/22 2/14/23 5/12/23 8/14/23 8/14/23 11/14/23 2/14/24 5/13/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - 3,170 101 2,314 - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -4,307 - - -2,850 -5,853 -1,528 -2,745
ROE (net income / shareholders' equity) -54.6% -59.6% -79.4% -92.8% -123% -170% -
ROA (Net income/ Total Assets) - -18.9% -27.3% -24% -23% - -
Assets 1 - 25,938 18,913 15,914 14,300 - -
Book Value Per Share 2 152.0 157.0 69.30 51.70 37.80 4.600 -18.60
Cash Flow per Share 2 -103.0 -88.40 -83.90 -52.90 -35.30 -31.60 -21.30
Capex 1 362 245 250 28 400 400 400
Capex / Sales 1,340.74% 597.56% 277.78% 23.14% 133.33% 28.73% 17.36%
Announcement Date 2/12/21 2/14/22 2/14/23 2/14/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
183 JPY
Average target price
280 JPY
Spread / Average Target
+53.01%
Consensus
  1. Stock Market
  2. Equities
  3. 4593 Stock
  4. Financials Healios K.K.